Drugs / ASP4345
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02720263 | Mar 2016 → Jun 2017 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03557931 | Jul 2018 → Oct 2019 | schizophrenia | Astellas Pharma Global Development, Inc. | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP4345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02720263 ↗ |
| Action | Activate | “positive allosteric modulator” PMID 33203954 ↗ Nov 2020 |
| Modality | Small molecule | “new chemical entity” PMID 33203954 ↗ Nov 2020 |
| Route | Oral | “oral administration” NCT03557931 ↗ |